A Single Dose Study of LY3023703 in Healthy Participants



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 60
Updated:8/8/2018
Start Date:June 2012
End Date:September 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects

This is a phase I study of LY3023703 in healthy participants. The purposes of this study are
to look at safety, how well the study drug is tolerated, how much of the study drug gets into
the blood stream, and how long it takes the body to get rid of it when given to humans.
Information about any side effects that may occur will also be collected. Participants will
remain in the study for approximately 3 months. This study is for research purposes only and
is not intended to treat any medical condition.


Inclusion Criteria:

- Overtly healthy individuals based on the history and physical examinations as
determined by the investigator

- Body mass index between 18.5 and 32.0 kilograms per square meter (kg/m^2), inclusive

Exclusion Criteria:

- Have known allergies to LY3023703 or any components of the formulation, celecoxib, or
sulfonamides. Participants with known aspirin allergy, allergic reaction to
nonsteroidal anti-inflammatory drugs (NSAIDs), or allergies or intolerance to other
selective microsomal prostaglandin E synthase (mPGES-1) inhibitors should also be
excluded

- Have the presence of active peptic ulcer disease, gastrointestinal (GI) bleeding,
chronic gastritis, inflammatory bowel disease, or chronic diarrhea, or positive
Helicobacter pylori serology

- Use NSAIDs, celecoxib, aspirin, or acetaminophen (at doses greater than 1 gram per
day) within 14 days of screening
We found this trial at
1
site
Clinical Trial Facility in Evansville Indiana
Evansville, Indiana 47713
?
mi
from
Evansville, IN
Click here to add this to my saved trials